Exploiting synthetic lethal interactions for targeted cancer therapy.

TitleExploiting synthetic lethal interactions for targeted cancer therapy.
Publication TypeJournal Article
Year of Publication2009
AuthorsReinhardt, HC, Jiang, H, Hemann, MT, Yaffe, MB
JournalCell Cycle
Volume8
Issue19
Pagination3112-9
Date Published2009 Oct 1
ISSN1551-4005
KeywordsAnimals, BRCA1 Protein, BRCA2 Protein, Cell Cycle Proteins, DNA Damage, DNA Repair, DNA-Binding Proteins, Humans, Mice, Neoplasms, Oncogenes, Poly(ADP-ribose) Polymerases, Protein-Serine-Threonine Kinases, Tumor Suppressor Protein p53, Tumor Suppressor Proteins
Abstract

Emerging data suggests that synthetic lethal interactions between mutated oncogenes/tumor suppressor genes and molecules involved in DNA damage signaling and repair can be therapeutically exploited to preferentially kill tumor cells. In this review, we discuss the concept of synthetic lethality, and describe several recent examples in which this concept was successfully implemented to target tumor cells in culture, in mouse models, and in human cancer patients.

Alternate JournalCell Cycle
PubMed ID19755856
PubMed Central IDPMC3057180
Grant ListCA112967 / CA / NCI NIH HHS / United States
ES015339 / ES / NIEHS NIH HHS / United States
GM68762 / GM / NIGMS NIH HHS / United States
P50 GM068762-08 / GM / NIGMS NIH HHS / United States
R01 ES015339-05 / ES / NIEHS NIH HHS / United States
U54 CA112967-03 / CA / NCI NIH HHS / United States
U54-CA112967-03 / CA / NCI NIH HHS / United States